Literature DB >> 16895556

Anti-idiotype antibody induced cellular immunity in mice transgenic for human carcinoembryonic antigen.

Asim Saha1, Sunil K Chatterjee, Kenneth A Foon, Malaya Bhattacharya-Chatterjee.   

Abstract

In the present study, we have analysed the detailed cellular immune mechanisms involved in tumour rejection in carcinoembryonic antigen (CEA) transgenic mice after immunization with dendritic cells (DC) pulsed with an anti-idiotype (Id) antibody, 3H1, which mimics CEA. 3H1-pulsed DC vaccinations resulted in induction of CEA specific cytotoxic T lymphocyte (CTL) responses in vitro and the rejection of CEA-transfected MC-38 murine colon carcinoma cells, C15, in vivo (Saha et al.,Cancer Res 2004; 64: 4995-5003). These CTL mediated major histocompatibility complex (MHC) class I-restricted tumour cell lysis, production of interferon-gamma (IFN-gamma) and tumour necrosis factor-alpha (TNF-alpha), and expression of Fas ligand (FasL) and TNF-related apoptosis-inducing ligand (TRAIL) in response to C15 cells. CTL used perforin-, FasL-, and TRAIL-mediated death pathways to lyse C15 cells, although perforin-mediated killing was the predominant lytic mechanism in vitro. The cytokines IFN-gamma and TNF-alpha synergistically enhanced surface expression of Fas, TRAIL receptor, MHC class I and class II on C15 cells that increased the sensitivity of tumour cells to CTL lysis. CTL activity generated in 3H1-pulsed DC immunized mice was directed against an epitope defined by the idio-peptide LCD-2, derived from 3H1. In vivo lymphocyte depletion experiments demonstrated that induction of CTL response and antitumour immunity was dependent on both CD4+ and CD8+ T cells. The analysis of splenocytes of immunized mice that had rejected C15 tumour growth revealed up-regulated surface expression of memory phenotype Ly-6C and CD44 on both CD4+ and CD8+ T cells. The adoptive transfer experiments also suggested the role of both CD4+ and CD8+ T cells in this model system. Furthermore, mice that had rejected C15 tumour growth, developed tumour-specific immunological memory.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16895556      PMCID: PMC1782317          DOI: 10.1111/j.1365-2567.2006.02391.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  50 in total

1.  Peptide loading of empty major histocompatibility complex molecules on RMA-S cells allows the induction of primary cytotoxic T lymphocyte responses.

Authors:  M L De Bruijn; T N Schumacher; J D Nieland; H L Ploegh; W M Kast; C J Melief
Journal:  Eur J Immunol       Date:  1991-12       Impact factor: 5.532

2.  Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains.

Authors:  K C Parker; M A Bednarek; J E Coligan
Journal:  J Immunol       Date:  1994-01-01       Impact factor: 5.422

3.  Murine monoclonal anti-idiotype antibody as a potential network antigen for human carcinoembryonic antigen.

Authors:  M Bhattacharya-Chatterjee; S Mukerjee; W Biddle; K A Foon; H Köhler
Journal:  J Immunol       Date:  1990-10-15       Impact factor: 5.422

4.  Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival.

Authors:  Hongkui Jin; Renhui Yang; Sharon Fong; Klara Totpal; David Lawrence; Zhong Zheng; Jed Ross; Hartmut Koeppen; Ralph Schwall; Avi Ashkenazi
Journal:  Cancer Res       Date:  2004-07-15       Impact factor: 12.701

5.  Dendritic cells pulsed with an anti-idiotype antibody mimicking carcinoembryonic antigen (CEA) can reverse immunological tolerance to CEA and induce antitumor immunity in CEA transgenic mice.

Authors:  Asim Saha; Sunil K Chatterjee; Kenneth A Foon; F James Primus; Sunil Sreedharan; Kartik Mohanty; Malaya Bhattacharya-Chatterjee
Journal:  Cancer Res       Date:  2004-07-15       Impact factor: 12.701

6.  Fine specificity of high molecular weight-melanoma-associated antigen-specific cytotoxic T lymphocytes elicited by anti-idiotypic monoclonal antibodies in patients with melanoma.

Authors:  James L Murray; Michael Gillogly; Kouichiro Kawano; Clay L Efferson; Jeffrey E Lee; Merrick Ross; Xinhui Wang; Soldano Ferrone; Constantin G Ioannides
Journal:  Cancer Res       Date:  2004-08-01       Impact factor: 12.701

7.  A novel CEA vaccine stimulates T cell proliferation, gammaIFN secretion and CEA specific CTL responses.

Authors:  T Parsons; I Spendlove; R Nirula; M Writer; G Carter; F Carr; L G Durrant
Journal:  Vaccine       Date:  2004-09-03       Impact factor: 3.641

8.  Molecular mimicry of hepatitis B surface antigen by an anti-idiotype-derived synthetic peptide.

Authors:  M W Pride; H Shi; J M Anchin; D S Linthicum; P T LoVerde; A Thakur; Y Thanavala
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-15       Impact factor: 11.205

Review 9.  The Fas death factor.

Authors:  S Nagata; P Golstein
Journal:  Science       Date:  1995-03-10       Impact factor: 47.728

10.  Induction of cytotoxic T lymphocytes by primary in vitro stimulation with peptides.

Authors:  F R Carbone; M W Moore; J M Sheil; M J Bevan
Journal:  J Exp Med       Date:  1988-06-01       Impact factor: 14.307

View more
  6 in total

1.  scFv6.C4 DNA vaccine with fragment C of Tetanus toxin increases protective immunity against CEA-expressing tumor.

Authors:  Bianca Ferrarini Zanetti; Camila Pontes Ferreira; José Ronnie Carvalho de Vasconcelos; Sang Won Han
Journal:  Gene Ther       Date:  2019-02-15       Impact factor: 5.250

2.  Role of apoptosis resistance in immune evasion and metastasis of colorectal cancer.

Authors:  Kebin Liu
Journal:  World J Gastrointest Oncol       Date:  2010-11-15

Review 3.  Potential targets for pancreatic cancer immunotherapeutics.

Authors:  Lindzy F Dodson; William G Hawkins; Peter Goedegebuure
Journal:  Immunotherapy       Date:  2011-04       Impact factor: 4.196

4.  Idiotypes as immunogens: facing the challenge of inducing strong therapeutic immune responses against the variable region of immunoglobulins.

Authors:  Alejandro López-Requena; Oscar R Burrone; Michela Cesco-Gaspere
Journal:  Front Oncol       Date:  2012-11-09       Impact factor: 6.244

5.  Combined effects of 5-fluorouracil, folinic acid and oxaliplatin on the expression of carcinoembryonic antigen in human colon cancer cells: pharmacological basis to develop an active antitumor immunochemotherapy.

Authors:  Salvatore P Prete; Mario Turriziani; Maria C Massara; Alessia De Rossi; Pierpaolo Correale; Liana De Vecchis; Francesco Torino; Laura Bonmassar; Angelo Aquino
Journal:  J Exp Clin Cancer Res       Date:  2008-05-19

6.  iCa2+ Flux, ROS and IL-10 Determines Cytotoxic, and Suppressor T Cell Functions in Chronic Human Viral Infections.

Authors:  Subhasmita Mohanty; Prakash Barik; Nagen Debata; Perumal Nagarajan; Satish Devadas
Journal:  Front Immunol       Date:  2020-03-06       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.